Gastroenterology Learning Network IBD Drive Time: Russell Cohen, MD, on New Therapies for IBD
Dec 20, 2023
Russell Cohen, MD, expert in IBD and new therapies, discusses the advantages of the subcutaneous formulation of vetilismab over the IV formulation, the effectiveness of Atrasimod for ulcerative colitis, and the introduction of Mira Kizumab as the first IL-23 inhibitor for ulcerative colitis.
Chapters
Transcript
Episode notes
1 2 3 4 5
Introduction
00:00 • 3min
Comparing Efficacy and Transitioning of Subcutaneous Therapy for IBD
03:09 • 8min
Atrasimod: A Promising Therapy for Ulcerative Colitis
11:23 • 6min
New Therapies for IBD: A Trasimod and Mira Kizumab
17:27 • 3min
Discussion on Sub-Q version of Merikizumab and its Injection Process
20:49 • 2min